Andreas Schneeweiß

52.5k total citations · 10 hit papers
608 papers, 19.1k citations indexed

About

Andreas Schneeweiß is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Schneeweiß has authored 608 papers receiving a total of 19.1k indexed citations (citations by other indexed papers that have themselves been cited), including 461 papers in Oncology, 307 papers in Cancer Research and 225 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Schneeweiß's work include Breast Cancer Treatment Studies (218 papers), Cancer Treatment and Pharmacology (197 papers) and HER2/EGFR in Cancer Research (170 papers). Andreas Schneeweiß is often cited by papers focused on Breast Cancer Treatment Studies (218 papers), Cancer Treatment and Pharmacology (197 papers) and HER2/EGFR in Cancer Research (170 papers). Andreas Schneeweiß collaborates with scholars based in Germany, United States and Switzerland. Andreas Schneeweiß's co-authors include Javier Cortés, Christof Sohn, Hans‐Peter Sinn, Klaus Pantel, Frederik Marmé, José Baselga, Eva Ciruelos, Sung‐Bae Kim, Graham Ross and Sandra M. Swain and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Andreas Schneeweiß

578 papers receiving 18.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

2015 1.4k citations José Baselga, Andreas Schneeweiß et al. profile →
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

2019 846 citations Andreas Schneeweiß et al. profile →
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

2013 836 citations Andreas Schneeweiß, Sabine Riethdorf et al. profile →
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

2013 774 citations Andreas Schneeweiß et al. profile →
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2013 700 citations Andreas Schneeweiß, José Baselga et al. profile →
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2010 700 citations Arlene Chan, Nadia Harbeck et al. Journal of Clinical Oncology profile →
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

2014 472 citations Hans Tesch, Peter A. Fasching et al. profile →
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

2021 293 citations Andreas Schneeweiß et al. profile →
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

2021 205 citations Andreas Schneeweiß et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. profile →

Peers

Countries citing papers authored by Andreas Schneeweiß

Since Specialization

Citations

This map shows the geographic impact of Andreas Schneeweiß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Schneeweiß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Schneeweiß more than expected).

Fields of papers citing papers by Andreas Schneeweiß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Schneeweiß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Schneeweiß. The network helps show where Andreas Schneeweiß may publish in the future.

Co-authorship network of co-authors of Andreas Schneeweiß

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Schneeweiß. A scholar is included among the top collaborators of Andreas Schneeweiß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Schneeweiß. Andreas Schneeweiß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biopsy‐derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility 2025 ·International Journal of Cancer ·(unknown), Roberto Würth, (unknown), Laura L. Michel, Verena Thewes, (unknown), Huriye Seker‐Cin, Daniel Kazdal, (unknown), (unknown), (unknown), (unknown), (unknown), Albrecht Stenzinger, Marc Zapatka, Peter Lichter, Andreas Schneeweiß, Andreas Trumpp, Martin R. Sprick	0
2	Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study. 2024 ·Journal of Clinical Oncology ·Frederik Marmé, Felix Hilpert, Manfred Welslau, Jacek Grabowski, Andreas Schneeweiß, Andreas Hartkopf, Dirk Bauerschlag, Peter A. Fasching, (unknown), (unknown), (unknown), Jalid Sehouli	0
3	Palliative Radiotherapy for Symptomatic Locally Advanced Breast Cancer 2023 ·Technology in Cancer Research & Treatment ·(unknown), Eva Meixner, Philipp Hoegen, (unknown), Fabian Weykamp, Tobias Förster, Maria Vinsensia, Kristin Lang, Laila König, Nathalie Arians, Carlo Fremd, Laura L. Michel, Katharina Smetanay, Andreas Schneeweiß, Markus Wallwiener, Jürgen Debus, Juliane Hörner‐Rieber	5
4	Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial 2023 ·Radiation Oncology ·Eva Meixner, (unknown), Tobias Förster, Fabian Weykamp, Kristin Lang, Laila König, Katja Lindel, (unknown), Johannes Krisam, Andreas Schneeweiß, M. Ellerbrock, (unknown), Juliane Hörner‐Rieber, Klaus Herfarth, Jürgen Debus, Nathalie Arians	7
5	Neoadjuvant and adjuvant end-points in health technology assessment in oncology 2021 ·European Journal of Cancer ·Nadia Harbeck, Andreas Schneeweiß, Peter Thuss‐Patience, Kurt Miller, Claus Garbe, Frank Griesinger, Wilfried Eberhardt, Jens Peter Klußmann, Barbara Wollenberg, Marc‐Oliver Grimm, Thomas Zander, Diana Lüftner	9
6	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial 2021 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Enio Gjerga, Steffen Hennig, Sigrid Schaper, Il‐Kang Na, Ulrich Keller, Sara Y. Brucker, Thomas Decker, Peter A. Fasching, Tanja Fehm, Wolfgang Janni, Sherko Kümmel, Andreas Schneeweiß, Martin Schüler, Diana Lüftner, Antonia Busse	19
7	Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial 2021 ·Journal of Medical Internet Research ·Joachim Graf, (unknown), (unknown), Lina Maria Matthies, Thomas M. Deutsch, Elisabeth Simoes, (unknown), (unknown), Andreas D. Hartkopf, Christina Barbara Walter, Markus Hahn, Tobias Engler, Stephanie Wallwiener, Florian Schuetz, Peter A. Fasching, Andreas Schneeweiß, Sara Y. Brucker, Markus Wallwiener	7
8	Chromothripsis in Human Breast Cancer 2020 ·Cancer Research ·Michiel Bolkestein, John Wong, Verena Thewes, Verena Körber, Mario Hlevnjak, (unknown), Markus Schulze, F. Kommoss, Hans‐Peter Sinn, Tobias Anzeneder, Steffen Hirsch, Frauke Devens, (unknown), Thomas Höfer, Andreas Schneeweiß, Peter Lichter, Marc Zapatka, Aurélie Ernst	17
9	Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication? 2020 ·Cancers ·Tobias Förster, (unknown), Rami A. El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura L. Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Joerg Heil, Andreas Schneeweiß, Jürgen Debus, Juliane Hörner‐Rieber	2
10	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial 2020 ·Journal of the American Heart Association ·(unknown), Andreas Schneeweiß, Sabine Seiler, Hans Tesch, Marion van Mackelenbergh, Frederik Marmé, Kristina Lübbe, Bruno V. Sinn, Thomas Karn, Elmar Stickeler, Volkmar Müller, Christian Schem, Carsten Denkert, Peter A. Fasching, Valentina Nekljudova, (unknown), Gerd Hasenfuß, Wilhelm Haverkamp, Sibylle Loibl, Stephan von Haehling	26
11	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study 2018 ·Journal of Medical Internet Research ·Lina Maria Matthies, Florin‐Andrei Taran, (unknown), Andreas Schneeweiß, Elisabeth Simoes, Andreas Hartkopf, Alexander N. Sokolov, Christina Barbara Walter, (unknown), Stephanie Wallwiener, Manuel Feißt, Paul Gaß, Michael P. Lux, Florian Schuetz, Peter A. Fasching, Christof Sohn, Sara Y. Brucker, Joachim Graf, Markus Wallwiener	27
12	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients 2017 ·JMIR Cancer ·Andreas Hartkopf, Joachim Graf, Elisabeth Simoes, (unknown), (unknown), Paul Gaß, D. Wallwiener, Lina Maria Matthies, Florin‐Andrei Taran, Michael P. Lux, Stephanie Wallwiener, (unknown), Christof Sohn, Peter A. Fasching, Andreas Schneeweiß, Sara Y. Brucker, Markus Wallwiener	35
13	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. 2016 ·PubMed ·Andreas Schneeweiß, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, (unknown), (unknown), Claudia Schumacher, (unknown), Claudia Kiewitz, (unknown), Marcus Schmidt	10
14	Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer 2015 ·Cancer Research ·Verena Thewes, Ronald Simon, (unknown), Magdalena Schlotter, Tobias Anzeneder, Reinhard Büttner, Vladimı́r Beneš, Guido Sauter, Barbara Burwinkel, Robert I. Nicholson, Hans‐Peter Sinn, Andreas Schneeweiß, Ulrich Deuschle, Marc Zapatka, Stefanie Heck, Peter Lichter	35
15	Breast Cancers with a BRCA1 -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy 2014 ·Clinical Cancer Research ·Philip C. Schouten, Frederik Marmé, Sebastian Aulmann, Hans‐Peter Sinn, Hendrik F. van Essen, Bauke Ylstra, Michael Hauptmann, Andreas Schneeweiß, Sabine C. Linn	30
16	Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer 2013 ·Journal of Clinical Oncology ·José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada	298
17	Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer 2012 ·Clinical Cancer Research ·Dharanija Madhavan, Manuela Zucknick, Markus Wallwiener, Katarina Ćuk, (unknown), Martina Scharpff, Sarah Schott, Jörg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Riethdorf, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiß, Barbara Burwinkel	214
18	Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study 2010 ·Journal of Clinical Oncology ·Volker Moebus, Christian Jackisch, Hans-Joachim Lueck, Andreas du Bois, Christoph Thomssen, Christian M. Kurbacher, Walther Kuhn, Ulrike Nitz, Andreas Schneeweiß, Jens Huober, Nadia Harbeck, Gϋnter von Minckwitz, Ingo B. Runnebaum, Axel Hinke, R. Kreienberg, Gottfried E. Konecny, Michael Untch	126
19	Estrogen-Related Receptor α Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast Carcinoma 2009 ·Cancer Research ·Stefanie Heck, Joachim Rom, Verena Thewes, Natália Becker, Beatrix Blume, Hans‐Peter Sinn, Ulrich Deuschle, Christof Sohn, Andreas Schneeweiß, Peter Lichter	29
20	Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer–Specific Immune Responses and Their Correlation to Prognosis 2009 ·Cancer Research ·Christoph Domschke, Florian Schuetz, Yingzi Ge, Tobias Seibel, Christine S. Falk, Benedikt Brors, Israël Vlodavsky, Nora Sommerfeldt, Hans‐Peter Sinn, (unknown), Andreas Schneeweiß, Alexander Scharf, Christof Sohn, Volker Schirrmacher, Gerhard Moldenhauer, Frank Momburg, Philipp Beckhove	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact